Zenas BioPharma recently presented new Phase 3 INDIGO data for obexelimab in immunoglobulin G4-related disease at the 6th ...
AI race continues apace, driven by those who reap the financial benefits, while ignoring those who lose their jobs. Where is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results